esaxerenone
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
5
Phase 4
0
Earliest trial started Jan 1, 2015 (NCT02345044)
Timeline
Indications
Mechanism of action
- Mineralocorticoid receptorANTAGONIST
NR3C2 antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545393 ↗
Also known as
- cs-3150
- cs-3150
- cs-3150
- xl550
- xl-550
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02890173 | Phase 3 | Sep 1, 2016 | Daiichi Sankyo |
| NCT02885662 | N/A | Sep 1, 2016 | Daiichi Sankyo |
| NCT02848170 | N/A | Aug 1, 2016 | Daiichi Sankyo |
| NCT02808026 | Phase 3 | Jun 1, 2016 | Daiichi Sankyo |
| NCT02807974 | Phase 3 | Jun 1, 2016 | Daiichi Sankyo |
| NCT02807987 | Phase 3 | Jun 1, 2016 | Daiichi Sankyo |
| NCT02722265 | Phase 3 | Mar 1, 2016 | Daiichi Sankyo |
| NCT04019652 | Phase 1 | Nov 19, 2015 | Daiichi Sankyo |
| NCT02448628 | Phase 2 | May 1, 2015 | Daiichi Sankyo |
| NCT02345057 | Phase 2 | Jan 1, 2015 | Daiichi Sankyo |
| NCT02345044 | Phase 2 | Jan 1, 2015 | Daiichi Sankyo |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 11 | 11 | 4 | 2015 |
1 organizations
Page 1 / 1